Treatment of leishmaniasis with miltefosine: 2008 status

Bibliography

• Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother 2005;6:1381-8
   PubMed Web of Science ®Google Scholar
• WHO: burden of disease. Available from: http://www.who.int/leishmaniasis/burden/en [Accessed 1 April 2008]
   Google Scholar
• Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43:917-24
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81
   PubMed Web of Science ®Google Scholar
• Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6
   PubMed Web of Science ®Google Scholar
• Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996;38:1041-7
   PubMed Web of Science ®Google Scholar
• Yardley V, Croft SL, De Doncker S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005;73:272-5
   PubMed Web of Science ®Google Scholar
• Hadighi R, Boucher P, Khamesipour A, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 2007;101:1319-22
   PubMed Web of Science ®Google Scholar
• Llull D, Rivas L, García E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci. Antimicrob Agents Chemother 2007;51:1844-8
   PubMed Web of Science ®Google Scholar
• Tong Z, Widmer F, Sorrell TC, et al. In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. Antimicrob Agents Chemother 2007;51:2219-22
   PubMed Web of Science ®Google Scholar
• Widmer F, Wright LC, Obando D, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006;50:414-21
   PubMed Web of Science ®Google Scholar
• Seifert K, Matu S, Javier Pérez-Victoria F, et al. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003;22:380-7
   PubMed Web of Science ®Google Scholar
• Pérez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003;47:2397-403
   PubMed Web of Science ®Google Scholar
• Pérez-Victoria FJ, Sánchez-Cañete MP, Castanys S, Gamarro F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem 2006;281:23766-75
   PubMed Web of Science ®Google Scholar
• Pérez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003;278:49965-71
   PubMed Web of Science ®Google Scholar
• Seifert K, Pérez-Victoria FJ, Stettler M, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 2007;30:229-35
   PubMed Web of Science ®Google Scholar
• Rakotomanga M, Blanc S, Gaudin K, et al. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007;51:1425-30
   PubMed Web of Science ®Google Scholar
• Luque-Ortega JR, Rivas L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007;51:1327-32
   PubMed Web of Science ®Google Scholar
• Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004;48:3010-5
   PubMed Web of Science ®Google Scholar
• Paris C, Bertoglio J, Bréard J. Lysosomal and mitochondrial pathways in miltefosine-induced apoptosis in U937 cells. Apoptosis 2007;12:1257-67
   PubMed Web of Science ®Google Scholar
• Zentaris AG. Impavido® registration certificate for miltefosine capsules 10 mg and 50 mg. Issued by German Registration Authority. 19 November 2004
   Google Scholar
• Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008;52(8):2855-60
   PubMed Web of Science ®Google Scholar
• Ménez C, Buyse M, Dugave C, et al. Intestinal absorption of miltefosine: contribution of passive paracellular transport. Pharm Res 2007;24:546-54
   PubMed Web of Science ®Google Scholar
• Ménez C, Buyse M, Farinotti R, Barratt G. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids 2007;42:229-40
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004;38:217-21
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007;196:591-8
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kumar A, Mitra G, et al. Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine. Indian J Med Res 2007;126:73-5
   PubMed Web of Science ®Google Scholar
• Singh UK, Prasad R, Mishra OP, Jayswal BP. Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study. Indian J Pediatr 2006;73:1077-80
   PubMedGoogle Scholar
• Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006;43:357-64
   PubMed Web of Science ®Google Scholar
• Troya J, Casquero A, Refoyo E, et al. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 2008;40:78-80
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007;44:350-6
   PubMed Web of Science ®Google Scholar
• Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990;113:934-40
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Echevarría J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997;25:677-84
   PubMed Web of Science ®Google Scholar
• Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78:210-1
   PubMed Web of Science ®Google Scholar
• Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007;103:33-40
   PubMed Web of Science ®Google Scholar
• Stojkovic M, Junghanss T, Krause E, Davidson RN. First case of typical Old World cutaneous leishmaniasis treated with miltefosine. Int J Dermatol 2007;46:385-7
   PubMed Web of Science ®Google Scholar
• Neub A, Krahl D, Stich A, Amon U. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Zerpa O, Blanco B, Kannee C, et al. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int J Dermatol 2006;45:751-3
   PubMed Web of Science ®Google Scholar
• Calvopina M, Gomez EA, Sindermann H, et al. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 2006;75:1074-7
   PubMed Web of Science ®Google Scholar
• Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007;156:1328-35
   PubMed Web of Science ®Google Scholar
• Sundar S, Kumar K, Chakravarty J, et al. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 2006;100:698-700
   PubMed Web of Science ®Google Scholar
• Ramesh V, Ansari NA, Jain RK, Salotra P. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Clin Exp Dermatol 2008;33:103-5
   PubMed Web of Science ®Google Scholar
• Schraner C, Hasse B, Hasse U, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 2005;40:e120-4
   PubMed Web of Science ®Google Scholar
• Belay AD, Asafa Y, Mesure J, Davidson RN. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Ann Trop Med Parasitol 2006;100:223-7
   PubMed Web of Science ®Google Scholar
• Sundar S. Combination liposomal amphotericin B and miltefosine for the treatment of visceral leishmaniasis in Northern Bihar, India [abstract no. 378]. 2007 Meeting; Philadelphia, PA, USA. Am Soc Trop Med Hyg 2007
   PubMedGoogle Scholar
• Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994;88:695-8
   PubMed Web of Science ®Google Scholar
• Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994;88:700-3
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Echevarria J, Seas C, et al. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am J Trop Med Hyg 2007;76:1128-31
   PubMed Web of Science ®Google Scholar